Literature DB >> 14684269

In vitro and in vivo correlation of buserelin release from biodegradable implants using statistical moment analysis.

Gesine Schliecker1, Carsten Schmidt, Stefan Fuchs, Andreas Ehinger, Jürgen Sandow, Thomas Kissel.   

Abstract

Here we investigated the possibility to develop different levels of correlation between in vitro drug release profiles and in vivo pharmacokinetic parameters for three Buserelin implant formulations. The in vitro and in vivo data were analyzed using model-independent and model-dependent methods. Since diffusion, dissolution and erosion effects influence drug release in most cases a simple kinetic model is unlikely to explain the overall in vivo release behavior. Thus the in vitro drug release curves were analyzed according to the theoretical models of Higuchi and Korsmeyer-Peppas. For the formulation with predominant diffusion controlled release level A IVIVC could be established (R2=0.986). Independent on drug release mechanism, a level B correlation between the mean in vitro dissolution time (MDT) and mean in vivo residence time (MRT) was obtained with a correlation coefficient of 0.983. Finally, level C correlation were observed when single in vitro parameters, e.g. T50% (time required to release 50% of drug in vitro) where compared with single in vivo parameters like AUC. This study suggests that a level B correlation could be achieved even when drug release occurs by a combination of diffusion and erosion processes. More sophisticated in vitro models mimicking drug release under in vivo conditions are clearly desirable for parenteral depot formulations.

Mesh:

Substances:

Year:  2004        PMID: 14684269     DOI: 10.1016/j.jconrel.2003.09.003

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  14 in total

Review 1.  In vitro-in vivo correlation for complex non-oral drug products: Where do we stand?

Authors:  Jie Shen; Diane J Burgess
Journal:  J Control Release       Date:  2015-09-28       Impact factor: 9.776

2.  In vitro and in vivo demonstration of risperidone implants in mice.

Authors:  C Rabin; Y Liang; R S Ehrlichman; A Budhian; K L Metzger; C Majewski-Tiedeken; K I Winey; S J Siegel
Journal:  Schizophr Res       Date:  2007-08-31       Impact factor: 4.939

3.  Accelerated in vitro release testing of implantable PLGA microsphere/PVA hydrogel composite coatings.

Authors:  Jie Shen; Diane J Burgess
Journal:  Int J Pharm       Date:  2011-10-13       Impact factor: 5.875

4.  FIP/AAPS joint workshop report: dissolution/in vitro release testing of novel/special dosage forms.

Authors:  Cynthia K Brown; Horst Dieter Friedel; Amy R Barker; Lucinda F Buhse; Susanne Keitel; Todd L Cecil; Johannes Kraemer; J Michael Morris; Christos Reppas; Mary P Stickelmeyer; Chikako Yomota; Vinod P Shah
Journal:  AAPS PharmSciTech       Date:  2011-06-18       Impact factor: 3.246

5.  A time scaling approach to develop an in vitro-in vivo correlation (IVIVC) model using a convolution-based technique.

Authors:  Cian Costello; Stefaan Rossenu; An Vermeulen; Adriaan Cleton; Adrian Dunne
Journal:  J Pharmacokinet Pharmacodyn       Date:  2011-07-07       Impact factor: 2.745

6.  In vitro-in vivo correlation of parenteral risperidone polymeric microspheres.

Authors:  Jie Shen; Stephanie Choi; Wen Qu; Yan Wang; Diane J Burgess
Journal:  J Control Release       Date:  2015-09-28       Impact factor: 9.776

Review 7.  In vitro dissolution testing models of ocular implants for posterior segment drug delivery.

Authors:  Muhammad Faris Adrianto; Febri Annuryanti; Clive G Wilson; Ravi Sheshala; Raghu Raj Singh Thakur
Journal:  Drug Deliv Transl Res       Date:  2021-08-11       Impact factor: 5.671

8.  In Vitro and In Vivo Correlation of Bone Morphogenetic Protein-2 Release Profiles from Complex Delivery Vehicles.

Authors:  Maurits G L Olthof; Marianna A Tryfonidou; Mahrokh Dadsetan; Wouter J A Dhert; Michael J Yaszemski; Diederik H R Kempen; Lichun Lu
Journal:  Tissue Eng Part C Methods       Date:  2018-07       Impact factor: 3.056

9.  A New Level A Type IVIVC for the Rational Design of Clinical Trials Toward Regulatory Approval of Generic Polymeric Long-Acting Injectables.

Authors:  Mahadevabharath R Somayaji; Debarun Das; Andrzej Przekwas
Journal:  Clin Pharmacokinet       Date:  2016-10       Impact factor: 6.447

10.  Doxorubicin eluting beads-2: methods for evaluating drug elution and in-vitro:in-vivo correlation.

Authors:  M Victoria Gonzalez; Yiqing Tang; Gary J Phillips; Andrew W Lloyd; Brenda Hall; Peter W Stratford; Andrew L Lewis
Journal:  J Mater Sci Mater Med       Date:  2007-07-25       Impact factor: 3.896

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.